Pink SheetA political official is negotiating the postmarketing commitment with Novavax that delayed its COVID-19 vaccine approval, continuing the pattern of highly unusual political involvement with the appl
Pink SheetSometimes the medium really is the message. When US FDA Commissioner Martin Makary declared the agency should be free from political influence, crediting his view may have been easier if he had not sa
Pink SheetThe US Food and Drug Administration has requested an unusual last-minute postmarketing commitment from Novavax to move the company’s COVID-19 vaccine to traditional approval, the company reported th
Pink SheetThe Advisory Committee on Immunization Practices’ first meeting under the Trump Administration provided an early public look at concerns that a top FDA official has about vaccine efficacy, safety and